Geron Corp (GERN):企業の財務・戦略的SWOT分析

◆英語タイトル:Geron Corp (GERN) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH42160FSA
◆発行会社(調査会社):GlobalData
◆発行日:2021年4月
◆ページ数:62
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD250 ⇒換算¥28,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥42,750見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Geron Corp (GERN) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Geron Corp (Geron) is a late-stage clinical biopharmaceutical company that focuses on the development and commercialization of imetelstat, a first-in-class telomerase inhibitor in hematologic myeloid malignancies. The company’s clinical studies include IMerge, a Phase 2 trial in lower risk myelodysplastic syndromes; and IMbark, a Phase 2 clinical trial in intermediate or high-risk myelofibrosis. Imetelstat received Fast Track designation from the US FDA to treat patients with transfusion-dependent anemia due to lower or intermediate risk myelodysplastic syndromes (MDS) and patients with intermediate or high-risk myelofibrosis (MF). The company utilizes core expertise in telomerase and telomere biology and its proprietary nucleic acid chemistry for the development of imetelstat. Geron is headquartered in Menlo Park, California, the US.

Geron Corp Key Recent Developments

Mar 11,2021: Geron Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights
Mar 01,2021: Geron to Announce Fourth Quarter and Full Year 2020 Financial Results on March 11, 2021
Nov 05,2020: Geron reports third quarter 2020 financial results and current events
Oct 29,2020: Geron to Announce Third Quarter Financial Results on November 5, 2020
Aug 06,2020: Geron reports second quarter 2020 financial results and current events

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Geron Corp – Key Facts
Geron Corp – Key Employees
Geron Corp – Key Employee Biographies
Geron Corp – Major Products and Services
Geron Corp – History
Geron Corp – Company Statement
Geron Corp – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Geron Corp – Business Description
R&D Overview
Geron Corp – SWOT Analysis
SWOT Analysis – Overview
Geron Corp – Strengths
Geron Corp – Weaknesses
Geron Corp – Opportunities
Geron Corp – Threats
Geron Corp – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Geron Corp, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Geron Corp, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Geron Corp, Recent Deals Summary
Section 5 – Company’s Recent Developments
Mar 11, 2021: Geron Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights
Mar 01, 2021: Geron to Announce Fourth Quarter and Full Year 2020 Financial Results on March 11, 2021
Nov 05, 2020: Geron reports third quarter 2020 financial results and current events
Oct 29, 2020: Geron to Announce Third Quarter Financial Results on November 5, 2020
Aug 06, 2020: Geron reports second quarter 2020 financial results and current events
May 28, 2020: Geron reports first quarter 2020 financial results
Mar 12, 2020: Geron reports fourth quarter and full year 2019 financial results and 2020 milestones
Feb 14, 2020: GERON: Departure of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officers
Jan 13, 2020: Geron announces 2019 accomplishments and key development priorities for 2020
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Geron Corp, Key Facts
Geron Corp, Key Employees
Geron Corp, Key Employee Biographies
Geron Corp, Major Products and Services
Geron Corp, History
Geron Corp, Other Locations
Geron Corp, Key Competitors
Geron Corp, Ratios based on current share price
Geron Corp, Annual Ratios
Geron Corp, Annual Ratios (Cont...1)
Geron Corp, Interim Ratios
Geron Corp, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Geron Corp, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Geron Corp, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[Geron Corp (GERN):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • The Dai-ichi Life Insurance Co Ltd:戦略・SWOT・企業財務分析
    The Dai-ichi Life Insurance Co Ltd - Strategy, SWOT and Corporate Finance Report Summary The Dai-ichi Life Insurance Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • GUD Holdings Limited (GUD):企業の財務・戦略的SWOT分析
    GUD Holdings Limited (GUD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Rehrig Pacific Company:企業の戦略的SWOT分析
    Rehrig Pacific Company - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Maruho Co Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Maruho Co Ltd (Maruho) is a pharmaceutical company that carries out the research, development, production, and distribution of dermatological products. It product portfolio includes a wide range of prescription drugs, medical devices and other skincare products. The company also offers produ …
  • India Glycols Ltd (INDIAGLYCO):企業の財務・戦略的SWOT分析
    India Glycols Ltd (INDIAGLYCO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Tokuyama Corporation (4043)-エネルギー分野:企業M&A・提携分析
    Summary Tokuyama Corporation (Tokuyama), formerly Nihon Soda Kogyo Co., Ltd., manufactures and sells chemicals, specialty products and cement. Its product portfolio includes soda ash, caustic soda, silicon products, vinyl chloride monomer/polymer, fine chemicals, film products, medical materials, me …
  • Walgreens Boots Alliance, Inc.:企業の戦略・SWOT・財務情報
    Walgreens Boots Alliance, Inc. - Strategy, SWOT and Corporate Finance Report Summary Walgreens Boots Alliance, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • FortisAlberta Inc.:企業の戦略的SWOT分析
    FortisAlberta Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …
  • Biocept Inc (BIOC):医療機器:M&Aディール及び事業提携情報
    Summary Biocept Inc (Biocept) is a molecular diagnostics company. The company develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA assays utilizing a standard blood sample. It offers assays for solid tumor indications, such as breast cancer, non-small cell l …
  • 3I Group Plc
    3I Group Plc - Strategy, SWOT and Corporate Finance Report Summary 3I Group Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Enka Power:企業の戦略的SWOT分析
    Enka Power - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. T …
  • Dohler GmbH:戦略・SWOT・企業財務分析
    Dohler GmbH - Strategy, SWOT and Corporate Finance Report Summary Dohler GmbH - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Helix BioPharma Corp (HBP):製薬・医療:M&Aディール及び事業提携情報
    Summary Helix BioPharma Corp (Helix) is a biopharmaceutical company with a focus in the field of cancer therapy. It develops drug candidates for the prevention and treatment of cancer. It develops drugs based on its proprietary technologies. DOS47, the company's proprietary broad anti-cancer therape …
  • Liberty Star Uranium & Metals Corp (LBSR):企業の財務・戦略的SWOT分析
    Summary Liberty Star Uranium & Metals Corp (Liberty Star), formerly Liberty Star Gold Corp is a mining and mineral exploration and development company that offers mineral resources. The company offers acquisition, exploration, operations, management, mining, production, and development of gold, copp …
  • BAE Systems Australia:企業の戦略・SWOT・財務情報
    BAE Systems Australia - Strategy, SWOT and Corporate Finance Report Summary BAE Systems Australia - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Program for Appropriate Technology in Health-製薬・医療分野:企業M&A・提携分析
    Summary Program for Appropriate Technology in Health (PATH) is a healthcare organization that offers vaccines, drugs, diagnostics, devices, system and service innovations, and digital health solutions. The organization offers HIV and AIDS, influenza, malaria and tuberculosis care services. It develo …
  • Ming Fai International Holdings Limited:企業の戦略・SWOT・財務情報
    Ming Fai International Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary Ming Fai International Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT a …
  • Tissue Genesis Inc-医療機器分野:企業M&A・提携分析
    Summary Tissue Genesis Inc (TGI) is a biotechnology company that provides services in the area of tissue engineering and cell therapy solutions. The company’s products include tissue genesis cell isolation system and icellator cell isolation system. It offers services such as repair restore and reju …
  • Proton Holdings Berhad:企業の戦略的SWOT分析
    Proton Holdings Berhad - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Emerson Electric Co (EMR):企業の財務・戦略的SWOT分析
    Emerson Electric Co (EMR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆